Recruiting studies: Recurrent Metastatic Head And Neck Squamous Cell Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizuma
Phase 2/Phase 3 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07554456 A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Ca
Phase 3 · 205 location(s) · Merus B.V. · NCT06525220 A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell C
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06006169 Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive
NA · 3 location(s) · Fondation Hôpital Saint-Joseph · NCT06061705 Establishment of a Microfluidic Based Liquid Biopsy Platform for Recurrent/Metastatic Head and Neck Cancers Prognosticat
Phase N/A · 1 location(s) · National Taiwan University Hospital · NCT06678724 BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196 A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma
Phase 1/Phase 2 · 1 location(s) · West China Hospital · NCT06753747 A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard
Phase 2 · 1 location(s) · Shanghai Henlius Biotech · NCT06769113 Efficacy and Safety of Paclitaxel Polymeric Micelles in Patients With Recurrent/Metastatic Head and Neck Squamous Cell C
Phase 2 · 1 location(s) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao · NCT07662746 A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06597565 Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and
Phase N/A · 1 location(s) · University of Rome Tor Vergata · NCT07448727 Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN
Phase 2 · 2 location(s) · Eye & ENT Hospital of Fudan University · NCT05260671 A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Meta
Phase 2 · 25 location(s) · Regeneron Pharmaceuticals · NCT06769698 A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor
Phase 1/Phase 2 · 10 location(s) · A2 Biotherapeutics Inc. · NCT06682793 Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors
Phase 1 · 1 location(s) · Therorna · NCT07081984 Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for R
Phase 2 · 8 location(s) · Gruppo Oncologico del Nord-Ovest · NCT06869473 A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metas
Phase 1/Phase 2 · 3 location(s) · Taipei Veterans General Hospital, Taiwan · NCT07136545 Iparomlimab and Tuvonralimab in HNSCC
Phase 2 · 1 location(s) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao · NCT07090317 Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Phase 1 · 30 location(s) · Calico Life Sciences LLC · NCT04777994 Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell
Phase 2 · 1 location(s) · Groupe Oncologie Radiotherapie Tete et Cou · NCT06640725 Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma
Phase 1/Phase 2 · 17 location(s) · Nykode Therapeutics ASA · NCT06016920 Oropharynx (OPX) Biomarker Trial
Phase N/A · 1 location(s) · Mayo Clinic · NCT06356272 Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC
Phase 2 · 1 location(s) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao · NCT06876844 A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurre
Phase 3 · 196 location(s) · Janssen Research & Development, LLC · NCT07276399 Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma
Phase 2 · 2 location(s) · Shanghai Institute Of Biological Products · NCT06194656 Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment
Phase 3 · 1 location(s) · Groupe Oncologie Radiotherapie Tete et Cou · NCT07264075 Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
Phase 1 · 1 location(s) · University of Chicago · NCT06912087 Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC
Phase 2 · 1 location(s) · Dan Zandberg · NCT06052839 A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07063212 A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients
Phase 1 · 16 location(s) · OncoNano Medicine, Inc. · NCT06022029

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.